Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.18 USD
Change Today 0.00 / 0.00%
Volume 113.9K
OCLS On Other Exchanges
Symbol
Exchange
OCLS is not on other exchanges.
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

oculus innovative sciences i (OCLS) Key Developments

Oculus Innovative Sciences, Inc. Announces Introduction of Alevicyn SG Antipruritic Spray Gel for Relief of Pain and Itch in Atopic Dermatitis

Oculus Innovative Sciences, Inc. announced the launch of the company's new Alevicyn SG Antipruritic Spray Gel for the prescription market via the company's dermatology division, IntraDerm Pharmaceuticals. Formulated with the patented Microcyn® Technology, Alevicyn SG Antipruritic Gel is indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including radiation dermatitis and atopic dermatitis. It may be also used to relieve the pain of first- and second-degree burns, and helps to relieve dry waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process. Alevicyn SG's unique formulation is a 'spray-on' that does not run or drip after application and no 'rubbing-in' is required on sensitive or difficult-to-access areas of the body. Oculus received FDA 510(k) clearance for the Alevicyn SG in May 2015 and is available nationwide at all chain and independent pharmacies via prescription.

Oculus Innovative Sciences, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2015

Oculus Innovative Sciences, Inc. reported unaudited consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported total revenues of $3,680,000 against $3,392,000 a year ago. Net loss was $2,340,000 against $70,000 a year ago. Net loss per common basic and diluted share was $0.15 against $0.01 a year ago. Loss from operations was $2,311,000 against $1,514,000 a year ago. The higher net loss was due to a $1.5 million gain due to a change in the fair value of derivative liabilities recognized for the three months ended June 30, 2014, and an increase in sales and marketing costs in the United States for the three months ended June 30, 2015, as compared to the same period in the prior year. Non-GAAP loss from operations minus non-cash expenses was $1,730,000 against $999,000 a year ago. Non-GAAP net loss minus non-cash expenses was $1,700,000 against $1,033,000 a year ago. Non-GAAP loss from operations minus non-cash expenses (LBITDAS) $1,730,000 against $999,000 a year ago. Non-GAAP net loss minus non-cash expenses was $1,700,000 against $1,033,000 a year ago.

Oculus Innovative Sciences, Inc. to Report Q1, 2016 Results on Jul 30, 2015

Oculus Innovative Sciences, Inc. announced that they will report Q1, 2016 results at 1:30 PM, Pacific Daylight on Jul 30, 2015

Oculus Innovative Sciences, Inc., Q1 2016 Earnings Call, Jul 30, 2015

Oculus Innovative Sciences, Inc., Q1 2016 Earnings Call, Jul 30, 2015

Oculus Innovative Sciences, Inc. Receives New U.S. Patent for Microcyn Technology in Treatment of Atopic Dermatitis

Oculus Innovative Sciences, Inc. announced the receipt of a new U.S. patent for the use of the Microcyn Technology hypochlorous acid in the treatment and mitigation of atopic dermatitis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCLS:US $1.18 USD 0.00

OCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,804 JPY +23.00
Henry Schein Inc $139.40 USD +0.72
Integra LifeSciences Holdings Corp $60.79 USD +0.25
Patterson Cos Inc $46.39 USD +0.45
Smith & Nephew PLC 1,163 GBp +29.00
View Industry Companies
 

Industry Analysis

OCLS

Industry Average

Valuation OCLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.3x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULUS INNOVATIVE SCIENCES I, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.